Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.
$2.57+0.78%
报价 2026-11-06
市值
$394.7M
EV
$286.8M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -31.5%
$1.67$3.75
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| EDITEditas Medicine, Inc. | $394.7M | +0.8% | -41.9% | 56.9% | – | – | – | |
| CAPRCapricor Therapeutics, Inc. | $521.2M | +4.7% | +18885.7% | 0% | – | 0.5x | – | |
| LYELLyell Immunopharma, Inc. | $364.1M | -0.9% | -100.0% | -8,537% | – | – | – | |
| ALLOAllogene Therapeutics, Inc. | $359.3M | -4.6% | – | 0% | – | – | – | |
| AVIRAtea Pharmaceuticals, Inc. | $345.7M | +2.1% | -19.7% | 0% | – | – | – | |
| KYTXKyverna Therapeutics, Inc. | $301.8M | +5.9% | +86.6% | 0% | – | – | – | |
| VNDAVanda Pharmaceuticals Inc. | $231M | +6.4% | +20.3% | 93.2% | – | – | – | |
| CABACabaletta Bio, Inc. | $220.4M | +1.6% | -43.2% | 0% | – | – | – | |
| PRQRProQR Therapeutics N.V. | $190.5M | +1.5% | – | 92.3% | – | – | – | |
| 同行中位数 | – | – | +0.3% | 0% | – | 0.5x | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。